Cargando…

Utility of the Infantile Hemangioma Referral Score (IHReS) as a decision-making tool for referral to treatment

BACKGROUND: The general paediatricians and primary care physicians sometimes face immense difficulty in referral judgements regarding which infantile hemangiomas (IHs) require referrals and when is the appropriate time to refer IHs for treatment. This resulted in the treatment being delayed beyond I...

Descripción completa

Detalles Bibliográficos
Autores principales: Chitpiromsak, Kanokporn, Techasatian, Leelawadee, Jetsrisuparb, Charoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8444243/
https://www.ncbi.nlm.nih.gov/pubmed/34604545
http://dx.doi.org/10.1136/bmjpo-2021-001230
_version_ 1784568448841416704
author Chitpiromsak, Kanokporn
Techasatian, Leelawadee
Jetsrisuparb, Charoon
author_facet Chitpiromsak, Kanokporn
Techasatian, Leelawadee
Jetsrisuparb, Charoon
author_sort Chitpiromsak, Kanokporn
collection PubMed
description BACKGROUND: The general paediatricians and primary care physicians sometimes face immense difficulty in referral judgements regarding which infantile hemangiomas (IHs) require referrals and when is the appropriate time to refer IHs for treatment. This resulted in the treatment being delayed beyond IHs’ critical timeframe. The Infantile Hemangioma Referral Score (IHReS) has been recently developed, with the aim to solve this problem. OBJECTIVES: The objective of the present study is to evaluate the reliability of IHReS and to assess the possibility of using this instrument in our country where a similar problem of delaying treatment of IHs is currently existing. METHODS: The present study was a prospective, cross-sectional study. Thirteen selected clinical cases were used to assess the reliability of IHReS among physicians who may have had the chance to deal with patients with IHs. The target physicians across the country were asked to participate in the study via an online platform (Google Forms) to decide whether to refer patients with IHs for treatment or observe. There were 3 steps of assessment: step 1, usual practice evaluation; step 2, using IHReS; step 3, retesting by using IHReS. RESULTS: Substantial agreement was observed after using IHReS (step 2) for interrater reliability, with Fleiss’ Kappa values of 0.80 and 0.78 among IH experts and non-expert physicians, respectively. Regarding repeatability, in the test–retest assessments, Cohen’s Kappa coefficient values revealed almost perfect agreement in intrarater repeatability for both experts and non-expert physicians (1.00). CONCLUSION: IHReS is a simple, easy-to-assess tool for non-expert physicians. The benefit in the increase of interrater agreement was found in both IH experts and non-expert physicians. It has had the reliability to be used in making referral decisions regarding patients with IH for treatment among Thai physicians. Using IHReS can improve clinical outcomes by identifying which patient needs early intervention to minimise the possible complications.
format Online
Article
Text
id pubmed-8444243
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-84442432021-10-01 Utility of the Infantile Hemangioma Referral Score (IHReS) as a decision-making tool for referral to treatment Chitpiromsak, Kanokporn Techasatian, Leelawadee Jetsrisuparb, Charoon BMJ Paediatr Open Dermatology BACKGROUND: The general paediatricians and primary care physicians sometimes face immense difficulty in referral judgements regarding which infantile hemangiomas (IHs) require referrals and when is the appropriate time to refer IHs for treatment. This resulted in the treatment being delayed beyond IHs’ critical timeframe. The Infantile Hemangioma Referral Score (IHReS) has been recently developed, with the aim to solve this problem. OBJECTIVES: The objective of the present study is to evaluate the reliability of IHReS and to assess the possibility of using this instrument in our country where a similar problem of delaying treatment of IHs is currently existing. METHODS: The present study was a prospective, cross-sectional study. Thirteen selected clinical cases were used to assess the reliability of IHReS among physicians who may have had the chance to deal with patients with IHs. The target physicians across the country were asked to participate in the study via an online platform (Google Forms) to decide whether to refer patients with IHs for treatment or observe. There were 3 steps of assessment: step 1, usual practice evaluation; step 2, using IHReS; step 3, retesting by using IHReS. RESULTS: Substantial agreement was observed after using IHReS (step 2) for interrater reliability, with Fleiss’ Kappa values of 0.80 and 0.78 among IH experts and non-expert physicians, respectively. Regarding repeatability, in the test–retest assessments, Cohen’s Kappa coefficient values revealed almost perfect agreement in intrarater repeatability for both experts and non-expert physicians (1.00). CONCLUSION: IHReS is a simple, easy-to-assess tool for non-expert physicians. The benefit in the increase of interrater agreement was found in both IH experts and non-expert physicians. It has had the reliability to be used in making referral decisions regarding patients with IH for treatment among Thai physicians. Using IHReS can improve clinical outcomes by identifying which patient needs early intervention to minimise the possible complications. BMJ Publishing Group 2021-09-15 /pmc/articles/PMC8444243/ /pubmed/34604545 http://dx.doi.org/10.1136/bmjpo-2021-001230 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Dermatology
Chitpiromsak, Kanokporn
Techasatian, Leelawadee
Jetsrisuparb, Charoon
Utility of the Infantile Hemangioma Referral Score (IHReS) as a decision-making tool for referral to treatment
title Utility of the Infantile Hemangioma Referral Score (IHReS) as a decision-making tool for referral to treatment
title_full Utility of the Infantile Hemangioma Referral Score (IHReS) as a decision-making tool for referral to treatment
title_fullStr Utility of the Infantile Hemangioma Referral Score (IHReS) as a decision-making tool for referral to treatment
title_full_unstemmed Utility of the Infantile Hemangioma Referral Score (IHReS) as a decision-making tool for referral to treatment
title_short Utility of the Infantile Hemangioma Referral Score (IHReS) as a decision-making tool for referral to treatment
title_sort utility of the infantile hemangioma referral score (ihres) as a decision-making tool for referral to treatment
topic Dermatology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8444243/
https://www.ncbi.nlm.nih.gov/pubmed/34604545
http://dx.doi.org/10.1136/bmjpo-2021-001230
work_keys_str_mv AT chitpiromsakkanokporn utilityoftheinfantilehemangiomareferralscoreihresasadecisionmakingtoolforreferraltotreatment
AT techasatianleelawadee utilityoftheinfantilehemangiomareferralscoreihresasadecisionmakingtoolforreferraltotreatment
AT jetsrisuparbcharoon utilityoftheinfantilehemangiomareferralscoreihresasadecisionmakingtoolforreferraltotreatment